Onglyza: Advanced DPP-4 Inhibitor for Type 2 Diabetes Management
| Product dosage: 5mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 14 | $4.54 | $63.50 (0%) | 🛒 Add to cart |
| 28 | $4.32 | $127.01 $120.96 (5%) | 🛒 Add to cart |
| 42 | $4.18 | $190.51 $175.39 (8%) | 🛒 Add to cart |
| 56 | $4.03 | $254.01 $225.79 (11%) | 🛒 Add to cart |
| 84 | $3.94 | $381.02 $330.62 (13%) | 🛒 Add to cart |
| 112 | $3.83 | $508.03 $429.40 (15%) | 🛒 Add to cart |
| 140 | $3.63
Best per pill | $635.03 $508.03 (20%) | 🛒 Add to cart |
Onglyza (saxagliptin) is a prescription medication indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It belongs to the dipeptidyl peptidase-4 (DPP-4) inhibitor class, which works by increasing the levels of incretin hormones to stimulate insulin release and reduce glucagon secretion. This oral therapy is designed for use as monotherapy or in combination with other antidiabetic agents, offering a targeted mechanism to help manage blood glucose levels with a favorable tolerability profile for many patients.
Features
- Active ingredient: Saxagliptin
- Available in 2.5 mg and 5 mg oral tablets
- DPP-4 enzyme inhibitor class
- Once-daily dosing regimen
- Not indicated for type 1 diabetes or diabetic ketoacidosis
- Can be used as monotherapy or in combination with metformin, sulfonylureas, or thiazolidinediones
- Manufactured under strict quality control standards
Benefits
- Enhances glucose-dependent insulin secretion for improved glycemic control
- Reduces fasting and postprandial glucose levels effectively
- Low risk of hypoglycemia when used as monotherapy
- Weight-neutral profile compared to some other antidiabetic agents
- Convenient once-daily dosing supports adherence
- Suitable for combination therapy to address complex treatment needs
Common use
Onglyza is commonly prescribed for the management of type 2 diabetes in adult patients when glycemic control is not adequately achieved through diet and exercise alone. It is often utilized as a second-line therapy after metformin or as part of a combination regimen with other oral antidiabetic drugs. Clinical studies support its use in various patient populations, including those with renal impairment (with dosage adjustment), making it a versatile option in comprehensive diabetes care plans.
Dosage and direction
The recommended dosage of Onglyza is 5 mg taken orally once daily, with or without food. For patients with moderate to severe renal impairment (creatinine clearance ≤50 mL/min) or end-stage renal disease requiring hemodialysis, the dosage should be reduced to 2.5 mg once daily. Tablets should be swallowed whole and not crushed, split, or chewed. Dosage adjustments may be necessary when used in combination with strong CYP3A4/5 inhibitors. Always follow the prescribing physician’s specific instructions regarding timing and concomitant medications.
Precautions
- Pancreatitis: Discontinue promptly if pancreatitis is suspected; do not restart if confirmed
- Hypersensitivity reactions: Monitor for symptoms including anaphylaxis, angioedema, or exfoliative skin conditions
- Renal impairment: Dose adjustment required for patients with CrCl ≤50 mL/min
- Hepatic impairment: Use with caution in patients with liver disease; monitor liver function
- Macrovascular outcomes: No clinical studies have confirmed reduced macrovascular risk
- Concomitant insulin use: May increase risk for hypoglycemia; consider insulin dose reduction
- Pregnancy: Use only if potential benefit justifies potential risk to fetus (Pregnancy Category B)
Contraindications
- History of serious hypersensitivity reaction to saxagliptin or any component of Onglyza
- Patients with type 1 diabetes or for the treatment of diabetic ketoacidosis
- Concomitant use with alogliptin, linagliptin, sitagliptin, or vildagliptin (other DPP-4 inhibitors)
- Severe gastrointestinal disease affecting drug absorption
- Known hereditary problems of galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption
Possible side effects
Common (≥5%):
- Upper respiratory tract infection
- Urinary tract infection
- Headache
- Nasopharyngitis
Less common (1-5%):
- Hypoglycemia (when used with sulfonylureas or insulin)
- Peripheral edema
- Gastrointestinal symptoms (nausea, vomiting, diarrhea)
- Rash
- Arthralgia
Rare (<1%):
- Acute pancreatitis
- Severe hypersensitivity reactions
- Hepatic enzyme elevations
- Bullous pemphigoid
- Heart failure (particularly in patients with history of heart failure or renal impairment)
Drug interaction
- Strong CYP3A4/5 inhibitors (e.g., ketoconazole, atazanavir, clarithromycin): May increase saxagliptin exposure; reduce Onglyza dose to 2.5 mg daily
- Insulin secretagogues (e.g., sulfonylureas) or insulin: May increase risk of hypoglycemia; consider lower dose of secretagogue or insulin
- CYP3A4 inducers (e.g., rifampin): May decrease saxagliptin efficacy; monitor glycemic control
- Angiotensin-converting enzyme inhibitors: Potential increased risk of angioedema
- No clinically significant interactions with metformin, glyburide, pioglitazone, digoxin, simvastatin, or diltiazem
Missed dose
If a dose of Onglyza is missed, it should be taken as soon as remembered on the same day. However, if it is almost time for the next scheduled dose, the missed dose should be skipped and the regular dosing schedule resumed. Do not take a double dose to make up for a missed dose. Maintain consistent timing of administration to ensure stable drug levels and optimal glycemic control.
Overdose
In the event of overdose, supportive measures should be instituted based on the patient’s clinical presentation. During clinical trials, doses up to 400 mg daily (80 times the recommended dose) for 2 weeks were not associated with significant clinical adverse effects. Hemodialysis may remove saxagliptin (approximately 23% removal over 4 hours); however, specific antidotes are not available. Monitor blood glucose levels and provide appropriate symptomatic treatment. Contact poison control center for latest guidance.
Storage
Store Onglyza tablets at room temperature between 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F). Keep in the original container with the lid tightly closed to protect from moisture. Keep out of reach of children and pets. Do not use beyond the expiration date printed on the packaging. Properly dispose of unused or expired medication according to local regulations.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Onglyza is available by prescription only and should be used under the supervision of a qualified healthcare professional. Individual patient responses may vary. Always consult with a physician or pharmacist for personalized medical advice, diagnosis, or treatment. Do not initiate or discontinue medication without professional guidance. Full prescribing information is available from the manufacturer.
Reviews
Clinical trials demonstrate Onglyza’s efficacy in reducing HbA1c by 0.4-0.9% when used as monotherapy and additional improvements in combination regimens. The saxagliptin assessment of vascular outcomes recorded in patients with diabetes (SAVOR-TIMI 53) trial showed effective glycemic control though with noted observations regarding heart failure hospitalization risk in susceptible populations. Many endocrinologists appreciate its once-daily dosing and low hypoglycemia risk profile. Patient satisfaction surveys indicate good tolerability, though some reports note limited efficacy in advanced disease states. Real-world evidence supports its position as a valuable option in the type 2 diabetes treatment algorithm, particularly for patients who cannot tolerate metformin or require add-on therapy.